{"id":43,"date":"2025-06-19T18:59:55","date_gmt":"2025-06-19T18:59:55","guid":{"rendered":"https:\/\/firdapsehcp-calems.local\/calems\/?page_id=33"},"modified":"2026-04-01T17:16:48","modified_gmt":"2026-04-01T17:16:48","slug":"about-firdapse","status":"publish","type":"page","link":"https:\/\/firdapsehcp.com\/ca-lems\/about-firdapse\/","title":{"rendered":"About FIRDAPSE"},"content":{"rendered":"\n
\n
\n

A compound that\u2019s unique<\/strong><\/strong><\/p>\n\n\n\n

FIRDAPSE is the first FDA-approved therapy that contains amifampridine, a voltage-gated potassium channel blocker targeting the presynaptic nerve terminal of neuromuscular junctions.2,22,23<\/sup><\/p>\n\n\n\n

FIRDAPSE works by blocking potassium channels on the presynaptic nerve terminal that cause action potential termination. This results in sustained calcium influx and increased ACh release at the neuromuscular junction.1,2,23,24<\/sup><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure><\/div><\/div>\n\n\n\n

Amifampridine phosphate<\/strong>
(3,4-diaminopyridine phosphate)1<\/sup><\/strong><\/p>\n<\/div>\n<\/div><\/div>\n\n\n\n

EXTENSIVELY TESTED<\/h2>\n\n\n\n

FIRDAPSE has been tested in >70 clinical and nonclinical studies, including 2 positive phase 3 studies, over a period of 9 years.1-3,2<\/sup><\/strong>4<\/sup><\/p>\n\n\n\n

FIRDAPSE demonstrated clinically meaningful muscle strength preservation and patient satisfaction in clinical trials.1-3<\/sup><\/p>\n\n\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\n\t
\n\t\t\n\t<\/div>\n\n
\n\t\n\n
\n
\n

\u22653600<\/h2>\n\n\n\n

patients in the United States are living with the challenges of LEMS2<\/sup><\/strong>4<\/sup><\/p>\n<\/div>\n\n\n\n

\n

>1200<\/h2>\n\n\n\n

patients have put their lives back in motion with FIRDAPSE2<\/sup><\/strong>4<\/sup><\/p>\n<\/div>\n<\/div><\/div>\n\n\n\n

The mechanism by which FIRDAPSE exerts its therapeutic effect in patients with LEMS has not been fully elucidated.1 <\/sup><\/p>\n\n\n\n

FIRDAPSE is a broad-spectrum potassium channel blocker.1<\/sup><\/p>\n\n\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\n\n\n

\n

FIRDAPSE MECHANISM OF ACTION (MOA)<\/h2>\n\n\n\n
\"\"<\/figure><\/div><\/div>\n\n\n\n
\n
\n
\"\"<\/a><\/figure><\/div><\/div>\n<\/div>\n\n\n\n
\n

See the full MOA story for LEMS and FIRDAPSE<\/strong><\/p>\n\n\n\n

Watch the full MOA animation video to better understand normal neuromuscular transmission, how LEMS disrupts this process, and how FIRDAPSE helps restore it.<\/p>\n\n\n\n

\n
Watch Video<\/span><\/span><\/a><\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n
\"\"<\/picture>
\n
\n
\n
\"\"<\/figure><\/div><\/div>\n<\/div>\n\n\n\n
\n

Using FIRDAPSE leads to an increase in ACh by targeting the presynaptic motor neuron, the source of neuromuscular dysfunction in those with LEMS.1,23<\/sup><\/p>\n<\/div>\n<\/div><\/div>\n<\/div><\/div><\/div>\n\n\n